Cargando…

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial

AIM: qPET is a quantitative method used to assess FDG-PET response in lymphoma. qPET was developed using 898 scans from children with Hodgkin Lymphoma (HL) in the EuroNet-PHL-C1 (C1) trial. The aim of this study was to determine if qPET could be applied as an alternative response method in adults in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Georgi, Thomas W., Kurch, Lars, Hasenclever, Dirk, Warbey, Victoria S., Pike, Lucy, Radford, John, Sabri, Osama, Kluge, Regine, Barrington, Sally F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117720/ https://www.ncbi.nlm.nih.gov/pubmed/32240248 http://dx.doi.org/10.1371/journal.pone.0231027

Ejemplares similares

Interobserver variability in interim PET assessment in Hodgkin lymphoma—reasons and solutions
por: Georgi, Thomas W., et al.
Publicado: (2023)

Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma
por: Kurch, Lars, et al.
Publicado: (2021)

FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas
por: Barrington, Sally F., et al.
Publicado: (2017)

Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin’s Lymphoma
por: Kluge, Regine, et al.
Publicado: (2016)

Automatic classification of lymphoma lesions in FDG-PET–Differentiation between tumor and non-tumor uptake
por: Georgi, Thomas W, et al.
Publicado: (2022)

End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET
por: Chohan, Karan L., et al.
Publicado: (2022)

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
por: André, M., et al.
Publicado: (2011)

PET/MR in children. Initial clinical experience in paediatric oncology using an integrated PET/MR scanner
por: Hirsch, Franz Wolfgang, et al.
Publicado: (2013)

Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin’s Lymphoma
por: Al-Ibraheem, Akram, et al.
Publicado: (2022)

Whole-body [(18)F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation
por: Kurch, L., et al.
Publicado: (2021)

Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy
por: Georgi, Thomas Walter, et al.
Publicado: (2023)

Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients
por: Furth, Christian, et al.
Publicado: (2013)

Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma
por: Liao, Cheng-Cheng, et al.
Publicado: (2017)

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment
por: Triumbari, Elizabeth Katherine Anna, et al.
Publicado: (2022)

Pediatric Hodgkin Lymphoma: Predictive value of interim (18)F-FDG PET/CT in therapy response assessment
por: Ferrari, Cristina, et al.
Publicado: (2017)

Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease
por: Tseng, Diane, et al.
Publicado: (2012)

CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin’s and aggressive non-hodgkin’s lymphomas
por: Ganeshan, B., et al.
Publicado: (2016)

Does Interim PET Scan After 2 Cycles of ABVD Predict Outcome in Hodgkin Lymphoma? Real-World Evidence
por: Seshachalam, Arun, et al.
Publicado: (2019)

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles
por: Rusconi, Chiara, et al.
Publicado: (2022)

The role of FDG-PET in Hodgkin lymphoma
por: Subocz, Edyta, et al.
Publicado: (2017)

Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report
por: Kurch, Lars, et al.
Publicado: (2022)

Moving the goalposts while scoring―the dilemma posed by new PET technologies
por: Rogasch, Julian M.M., et al.
Publicado: (2021)

P004: Advanced stage classical Hodgkin lymphoma (cHL) patients with a positive interim-PET (PET-2) Deauville score (DS) 5 after 2 ABVD cycles: A pooled analysis of individual patient data of three multicenter trials
por: Viviani, Simonetta, et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas
por: Barrington, Sally F., et al.
Publicado: (2016)

Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy
por: Procházka, Vít, et al.
Publicado: (2016)

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
por: Milgrom, Sarah A., et al.
Publicado: (2019)

In Vivo Correlation of Glucose Metabolism, Cell Density and Microcirculatory Parameters in Patients with Head and Neck Cancer: Initial Results Using Simultaneous PET/MRI
por: Gawlitza, Matthias, et al.
Publicado: (2015)

PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial
por: Picardi, M., et al.
Publicado: (2021)

PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma
por: Lang, Noemie, et al.
Publicado: (2020)

Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand
por: Boellaard, Ronald, et al.
Publicado: (2019)

Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine‐treated, interimPET‐negative classical Hodgkin Lymphoma patients: A radio‐genomic study
por: Durmo, Rexhep, et al.
Publicado: (2022)

Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients
por: Weisman, Amy J., et al.
Publicado: (2020)

FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
por: Voltin, Conrad-Amadeus, et al.
Publicado: (2020)

Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial: correlation with interim PET and outcome
por: Richter, Julia, et al.
Publicado: (2019)

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group
por: Daw, Stephen, et al.
Publicado: (2020)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
por: Eichenauer, Dennis A., et al.
Publicado: (2022)

Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
por: Seifert, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6kpvd41lu5k6psv5ui7as6d0v7